Rankings
▼
Calendar
AMLX FY 2020 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMLX
Amylyx Pharmaceuticals, Inc.
$1B
FY 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$650,000
-54.4% YoY
Gross Profit
-$24M
-3683.7% margin
Operating Income
-$39M
-6000.8% margin
Net Income
-$42M
-6504.6% margin
EPS (Diluted)
$-0.79
Cash Flow
Operating Cash Flow
-$37M
Free Cash Flow
-$37M
Stock-Based Comp.
$243,000
Balance Sheet
Total Assets
$14M
Total Liabilities
$81M
Stockholders' Equity
-$67M
Cash & Equivalents
$13M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$650,000
$1M
-54.4%
Gross Profit
-$24M
-$10M
-128.6%
Operating Income
-$39M
-$14M
-187.8%
Net Income
-$42M
-$15M
-185.4%
← FY 2019
All Quarters
Q4 2020 →